首页> 外文期刊>Journal of thrombosis and thrombolysis >New single nucleotide polymorphisms associated with differences in platelets reactivity in patients with type 2 diabetes treated with acetylsalicylic acid: Genome-wide association approach and pooled DNA strategy
【24h】

New single nucleotide polymorphisms associated with differences in platelets reactivity in patients with type 2 diabetes treated with acetylsalicylic acid: Genome-wide association approach and pooled DNA strategy

机译:与乙酰水杨酸治疗的2型糖尿病患者血小板反应性差异相关的新单核苷酸多态性:全基因组关联方法和合并DNA策略

获取原文
获取原文并翻译 | 示例
           

摘要

The objective of this study was to use genome-wide association approach and pooled DNA strategy to search for new genomic loci associated with inter-individual differences in platelet reactivity in the diabetic patients during acetylsalicylic acid (ASA) treatment. Study cohort consisted of 297 diabetic patients who had been taking ASA (75 mg daily) for at least 3 months. We tested association of single nucleotide polymorphisms (SNPs) genotyped using high density microarray platform with several platelet reactivity assays, followed by individual genotyping of most significant SNPs identified in the microarray genomic scan. The highest statistical significance (p value of 0.0001-0.008 in individual genotyping) was observed for SNP located within the regulatory G-protein signaling (RGS) 7 gene (rs2502448) using recessive genetic model. The diabetic patients on ASA treatment and homozygotes for its minor allele were characterized by increased odds ratio of at 3.45 (confidence interval: 1.82-6.53) for high on ASA platelet reactivity (i.e. impaired ASA response) when compared with homozygotes for wild-type allele. The genome-wide approach might provide an opportunity to identify novel candidate genes and pathways related to platelet activation in diabetic patients.
机译:这项研究的目的是使用全基因组关联方法和合并的DNA策略来寻找与乙酰水杨酸(ASA)治疗期间糖尿病患者的血小板反应性个体间差异相关的新基因组位点。研究队列包括297名糖尿病患者,他们服用ASA(每天75 mg)至少3个月。我们测试了使用高密度微阵列平台与几种血小板反应性测定进行基因分型的单核苷酸多态性(SNP)的关联,然后对在微阵列基因组扫描中鉴定的最重要的SNP进行了个体基因分型。使用隐性遗传模型,观察到位于调节性G蛋白信号(RGS)7基因(rs2502448)中的SNP具有最高的统计学显着性(单个基因分型的p值为0.0001-0.008)。与野生型等位基因的纯合子相比,接受ASA治疗的糖尿病患者及其次要等位基因的纯合子的特征在于,ASA血小板反应性高(即ASA反应受损)的比值比增加到3.45(置信区间:1.82-6.53)。 。全基因组方法可能为鉴定与糖尿病患者血小板活化相关的新候选基因和途径提供机会。

著录项

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号